Literature DB >> 9759684

Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution.

J Bladé1, P Fernández-Llama, F Bosch, J Montolíu, X M Lens, S Montoto, A Cases, A Darnell, C Rozman, E Montserrat.   

Abstract

BACKGROUND: Twenty percent of patients with multiple myeloma (MM) have renal failure.
OBJECTIVE: To analyze the presenting features, the response to therapy, and the factors associated with renal function recovery and survival in 94 patients with MM and renal failure. PATIENTS AND METHODS: Medical records of patients from our institution with MM and renal failure diagnosed between January 1969 and December 1994 were reviewed. The statistical methods consisted of Kaplan-Meier survival curves, the log-rank test, logistic regression analysis, and the Cox proportional hazards model for survival analysis.
RESULTS: Renal failure was observed in 94 (22.2%) of 423 patients. Patients with renal failure had more advanced disease than the others. Patients with renal failure had a lower response rate to chemotherapy than those with normal renal function (39% vs 56%; P<.001). However, when patients dying within the first 2 months of treatment were excluded, no significant differences in the response rate were found between patients with renal failure and those with normal renal function. Renal function recovery was observed in 26% of patients. Serum creatinine level (<354 micromol/L [<4 mg/dL]), serum calcium level (> or =2.88 mmol/L [> or = 11.5 mg/dL]), and amount of proteinuria (< 1 g/24 h) were associated with renal function recovery. Patients who recovered renal function had a median survival of 28 months vs 4 months for those with nonreversible renal failure (P<.001). In the multivariate analysis, only serum creatinine level (P=.003) and response to chemotherapy (P<.001) were correlated with survival.
CONCLUSIONS: Renal failure was present in almost one fourth of patients with MM. Patients with reversible renal failure had longer survival than those not recovering renal function. When patients dying within the first 2 months of treatment were excluded, the response rate was not affected by renal function. Factors associated with renal function recovery were degree of renal failure, presence of hypercalcemia, and amount of proteinuria. Response to chemotherapy and severity of renal failure were the only independent factors associated with survival.

Entities:  

Mesh:

Year:  1998        PMID: 9759684     DOI: 10.1001/archinte.158.17.1889

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  74 in total

1.  Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Paul W Sanders
Journal:  Am J Pathol       Date:  2011-11-10       Impact factor: 4.307

2.  Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Authors:  Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 3.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

4.  Renal impairment in multiple myeloma: presenting features in different departments.

Authors:  Ni Li; Yongman Lv; Hongbing Zeng; Fan He; Ying Yao; Xiaofeng He
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

Review 5.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

6.  Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Beth M Faiman; Patricia Mangan; Jacy Spong; Joseph D Tariman
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

Review 7.  Serum free light chain assessment in monoclonal gammopathy and kidney disease.

Authors:  Colin A Hutchison; Kolitha Basnayake; Paul Cockwell
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

Review 8.  Onco-nephrology: AKI in the cancer patient.

Authors:  Albert Q Lam; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 8.237

9.  Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures.

Authors:  Maeve P Crowley; Vinitha N Prabhakaran; Oonagh M Gilligan
Journal:  Pathol Oncol Res       Date:  2017-09-13       Impact factor: 3.201

10.  The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Authors:  Meletios Dimopoulos; Adrian Alegre; Edward A Stadtmauer; Hartmut Goldschmidt; Jeffrey A Zonder; Carlos M de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M Weber
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.